Johnson & Johnson (JNJ) EBT Margin (2009 - 2026)
Johnson & Johnson recorded quarterly EBT Margin of 24.89% in Q1 2026, up 23.14% quarter-over-quarter from 20.22% in Q4 2025, and down 3737.0% year-over-year from 0.68% in Q1 2025.
Johnson & Johnson's EBT Margin history runs 18 years deep, the most recent figure standing at 24.89% for Q1 2026.
- In Q1 2026, EBT Margin fell 3737.0% year-over-year to 24.89%; the TTM figure through Mar 2026 stood at 25.88% (down 390.0% YoY), while the FY2025 annual figure was 34.59%, up 1580.0% from the prior year.
- EBT Margin came in at 24.89% for Q1 2026 at Johnson & Johnson, up from 20.22% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 62.26% in Q1 2025 to a low of 6.16% in Q2 2023.
- A 5-year average of 24.0% and a median of 24.89% in 2026 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin jumped 4489 bps in 2025 and sank 3737 bps in 2026, its largest moves.
- Johnson & Johnson's EBT Margin stood at 25.87% in 2022, then fell by 13 bps to 22.56% in 2023, then dropped by 23 bps to 17.26% in 2024, then gained by 17 bps to 20.22% in 2025, then grew by 23 bps to 24.89% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 24.89%, 20.22%, and 31.23% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 28.20% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 24.89% |
| Dec 28, 2025 | 20.22% |
| Sep 28, 2025 | 31.23% |
| Jun 29, 2025 | 27.34% |
| Mar 30, 2025 | 62.26% |
| Dec 29, 2024 | 17.26% |
| Sep 29, 2024 | 14.85% |
| Jun 30, 2024 | 25.61% |
| Mar 31, 2024 | 17.37% |
| Dec 31, 2023 | 22.56% |
| Oct 1, 2023 | 24.43% |
| Jul 2, 2023 | 29.30% |
| Apr 2, 2023 | -6.16% |
| Jan 1, 2023 | 19.26% |
| Oct 2, 2022 | 25.87% |
| Jul 3, 2022 | 25.45% |
| Apr 3, 2022 | 26.22% |
| Oct 3, 2021 | 16.49% |
| Jul 4, 2021 | 28.58% |
| Apr 4, 2021 | 33.28% |
| Jan 3, 2021 | 7.33% |
| Sep 27, 2020 | 20.88% |
| Jun 28, 2020 | 21.49% |
| Mar 29, 2020 | 31.46% |
| Dec 29, 2019 | 20.33% |
| Sep 29, 2019 | 7.95% |
| Jun 30, 2019 | 34.24% |
| Mar 31, 2019 | 22.09% |
| Dec 30, 2018 | 15.31% |
| Sep 30, 2018 | 21.74% |
| Jul 1, 2018 | 23.87% |
| Apr 1, 2018 | 27.39% |
| Dec 31, 2017 | 12.68% |
| Oct 1, 2017 | 24.38% |
| Jul 2, 2017 | 25.20% |
| Apr 2, 2017 | 31.38% |
| Jan 1, 2017 | 23.88% |
| Oct 2, 2016 | 29.64% |
| Jul 3, 2016 | 26.53% |
| Apr 3, 2016 | 30.28% |
| Jan 3, 2016 | 21.10% |
| Sep 27, 2015 | 24.10% |
| Jun 28, 2015 | 32.28% |
| Mar 29, 2015 | 32.09% |
| Dec 28, 2014 | 14.81% |
| Sep 28, 2014 | 36.88% |
| Jun 29, 2014 | 28.86% |
| Mar 30, 2014 | 29.94% |
| Dec 29, 2013 | 14.98% |
| Sep 29, 2013 | 20.86% |
| Jun 30, 2013 | 26.81% |
| Mar 31, 2013 | 24.34% |
| Dec 30, 2012 | 17.66% |
| Sep 30, 2012 | 21.08% |
| Jul 1, 2012 | 12.35% |
| Apr 1, 2012 | 31.26% |
| Jan 1, 2012 | 1.96% |
| Oct 2, 2011 | 25.69% |
| Jul 3, 2011 | 20.62% |
| Apr 3, 2011 | 27.89% |
| Jan 2, 2011 | 14.24% |
| Oct 3, 2010 | 28.16% |
| Jul 4, 2010 | 27.53% |
| Apr 4, 2010 | 40.18% |
| Jan 3, 2010 | 15.73% |
| Sep 27, 2009 | 28.15% |
| Jun 28, 2009 | 27.97% |
| Mar 29, 2009 | 30.90% |